Cerezyme sales lift Genzyme in quarter
96500
Genzyme Corp. , the biotech firm expanding into the market for cancer treatments, said fourth-quarter revenue rose 23 percent to $591 million on higher sales of its Cerezyme treatment for Gaucher disease. Revenue increased from $481 million a year earlier, the Cambridge company said in an e-mailed statement. Profit for the full year 2004, excluding some items, rose to $1.75 ...
227799
Drugmakers Merck & Co.  and Schering-Plough Corp.  reported second-quarter results that handily topped Wall Street expectations on Monday, helped by increased sales of the cholesterol-lowering drugs they co-market and other medicines.
600885
GlaxoSmithKline, Europe's biggest drug maker, has booked a 14.9-percent increase in net profits for 2006, buoyed by soaring sales in the United States and despite a poor performance in Europe.
139031
Boston Scientific Corp. (BSX.N: Quote, Profile, Research) on Tuesday said its quarterly net earnings rose as sales of its new cardiovascular device bolstered results despite a costly recall.
570025
Swiss pharmaceutical giant Roche Group on Thursday announced third-quarter sales up 9 percent from the same period last year, driven by strong growth from its two leading cancer treatments.
230917
Biogen Idec reported Thursday that its fourth-quarter profit nearly doubled on growing sales of treatments for cancer and multiple sclerosis.
640089
Patterson Cos.  on reported slightly higher quarterly profit Wednesday on increased sales of its dental products.
249444
U.S. prescription drug sales rose 8.3 percent to $274 billion last year, fueled by the Medicare drug benefit, increased use of generic medicines and new treatments for diseases such as cancer and diabetes, according to a new report.
229274
Genentech, the biotechnology company, posted a 41 percent increase in second-quarter profit on sales of its cancer drugs, continuing a positive earnings streak.
139125
Genentech Inc. DNA.N on Wednesday  posted a 50 percent rise in quarterly profit and raised its  full-year earnings forecast on strong sales of its new colon  cancer drug, sending its shares higher in after-hours trading.
240983
Wyeth  on Thursday said its  second-quarter earnings rose on higher sales of its  prescription drugs.
567554
World&#39;s No.2 biotech company beats Wall Street consensus and raises its full-year profit forecast. NEW YORK  - Genentech Inc.
439296
Drugmaker Merck & Co. Inc.  boosted its 2007 earnings forecast on Wednesday, citing higher-than-expected sales of multiple products, including its cancer vaccine Gardasil and diabetes drug Januvia.
10796
Net profit in the fourth quarter rose to 753 million euros ($1.09 billion), helped by sales of the blood-thinner Plavix in the United States and cost-cutting measures, the company said.
551035
Merck & Co. on Monday said second-quarter earnings rose on higher sales of its new vaccines and medicines, and the company raised its 2007 profit forecast amid continuing strong demand for the medicines.
301333
NEW YORK  - Genzyme Corp. announced  Wednesday that its drug Clolar has been approved by the U.S.  Food and Drug Administration (FDA) for the treatment of  children with difficult or relapsed acute lymphoblastic  leukemia (ALL).
246930
Biotechnology company Genzyme Corp  reported a fourth-quarter profit on Wednesday, reversing a year-earlier loss, as sales of its drugs for rare diseases increased.